Indian Journal of Pharmacy and Pharmacology

Print ISSN: 2393-9079

Online ISSN: 2393-9087

CODEN : IJPPTK

Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, more...


Article type

Original Article


Article page

205-207


Authors Details

Abhijit Trailokya*, Amol Aiwale, Roshan Pawar, Suhas Erande


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 93

PDF Downloaded: 60


Retrospective, observational study on usage of evogliptin in T2DM patients: A real-World experience in Indian patients


Original Article

Author Details : Abhijit Trailokya*, Amol Aiwale, Roshan Pawar, Suhas Erande

Volume : 8, Issue : 3, Year : 2021

Article Page : 205-207

https://doi.org/10.18231/j.ijpp.2021.035



Suggest article by email


Abstract

Aim: This study aimed to assess effectiveness and safety of Evogliptin 5 mg in patients with T2DM who were prescribed Evogliptin alone or with other oral hypoglycemic agents in real world scenario.
Materials and Methods: Overall 20 patients who received Evogliptin as routine clinical practice in management of T2DM were analyzed retrospectively from single center. Data collected from past medical records. Primary endpoint was mean changes in HbA1c from baseline to weeks 24 and secondary endpoints were Change in HbA1c from baseline to weeks 12 Change from baseline in FPG & PPG at weeks 12 & 24.
Results: Significant reduction in HbA1c at the end of 12 and 24 weeks of Evogliptin therapy was - 0.9% and -1.45% respectively from the baseline of HbA1c 8.6% (p value <0> At the end of 12 and 24 weeks of addition of Evogliptin, significant reduction in FBG were seen i.e -49.5 mg/dl and -90.7mg/dl respectively from base line of 182 mg/dl and reduction in PPG was -79.4mg/dl and -116.6mg/dl respectively from base line 277 mg/dl (p value <0> Conclusion: Evogliptin was found to be effective when added to the patients who were uncontrolled on dual / triple oral anti-diabetic medications and even in treatment naïve patient. It effectively showed reduction in HbA1c, FBG and PPG and the end of 12 and 24 weeks when added to existing anti-diabetic medications & well tolerated in type 2 diabetes Indian patients.
Limitations: Small sample size and retrospective study


Keywords: PPG, FBG, DPP-4, T2DM


How to cite : Trailokya A, Aiwale A, Pawar R, Erande S, Retrospective, observational study on usage of evogliptin in T2DM patients: A real-World experience in Indian patients. Indian J Pharm Pharmacol 2021;8(3):205-207

Copyright © 2021 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (creativecommons.org)







Wiki in hindi